Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Joubert, B. Jagu, D. Montaigne, X. Maréchal, A. Tesse, A. Ayer, L. Dollet, C. May, G. Toumaniantz, A. Manrique, F. Charpentier, B. Staels, J. Magré, B. Cariou, X. Prieur (2017)
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse ModelDiabetes, 66
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation, 128 16
C. Bonner, J. Kerr-Conte, V. Gmyr, G. Quéniat, E. Moerman, Julien Thévenet, C. Beaucamps, N. Delalleau, Iuliana Popescu, W. Malaisse, A. Sener, B. Déprez, A. Abderrahmani, B. Staels, F. Pattou (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretionNature Medicine, 21
J. Higgins, D. Altman, P. Gøtzsche, P. Jüni, D. Moher, A. Oxman, J. Savović, K. Schulz, L. Weeks, J. Sterne (2011)
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsThe BMJ, 343
A. Singh, A. Unnikrishnan, A. Zargar, Ajay Kumar, A. Das, B. Saboo, B. Sinha, K. Gangopadhyay, P. Talwalkar, S. Ghosal, S. Kalra, S. Joshi, Surendra Sharma, U. Sriram, V. Mohan (2019)
Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in IndiansDiabetes Therapy, 10
D. Moher, A. Liberati, J. Tetzlaff, D. Altman (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA StatementOpen Medicine, 3
Merlin Thomas, D. Cherney (2018)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressureDiabetologia, 61
K. Birkeland, M. Jørgensen, B. Carstensen, F. Persson, H. Gulseth, M. Thuresson, P. Fenici, D. Nathanson, T. Nyström, J. Eriksson, J. Bodegård, A. Norhammar (2017)
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.The lancet. Diabetes & endocrinology, 5 9
Pongpan Tanajak, P. Sa-nguanmoo, Sivaporn Sivasinprasasn, Savitree Thummasorn, Natthaphat Siri-Angkul, S. Chattipakorn, N. Chattipakorn (2017)
Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury.The Journal of endocrinology, 236 2
E. Bertero, Leticia Roma, P. Ameri, C. Maack (2018)
Cardiac effects of SGLT2 inhibitors: the sodium hypothesisCardiovascular Research, 114
M. Mazidi, P. Rezaie, Hong‐kai Gao, A. Kengne (2017)
Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 PatientsJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6
W. Viechtbauer, M. Cheung (2010)
Outlier and influence diagnostics for meta‐analysisResearch Synthesis Methods, 1
S. Verma, J. McMurray (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art reviewDiabetologia, 61
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 62 16
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation, 128 16
J. Cohn, M. Pfeffer, J. Rouleau, N. Sharpe, K. Swedberg, M. Straub, C. Wiltse, T. Wright (2003)
Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON)European Journal of Heart Failure, 5
Sarayut Lahnwong, S. Chattipakorn, N. Chattipakorn (2018)
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitorsCardiovascular Diabetology, 17
S. Wiviott, I. Raz, M. Bonaca, Ofri Mosenzon, Eri Kato, A. Cahn, Michael Silverman, Thomas Zelniker, J. Kuder, S. Murphy, Deepak Bhatt, Lawrence Leiter, Darren Mcguire, J. Wilding, C. Ruff, I. Gause-Nilsson, M. Fredriksson, P. Johansson, A. Langkilde, M. Sabatine (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 380
Tsung-Ming Lee, Tsang‐Wei Chang, Chengmin Yang (2017)
Dapagliflozin, a Selective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat HeartsThe FASEB Journal, 31
Y. Ye, M. Bajaj, Hsiu‐Chiung Yang, J. Perez-Polo, Y. Birnbaum (2017)
SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 InhibitorCardiovascular Drugs and Therapy, 31
M. Nassif, Sheryl Windsor, F. Tang, Yevgeniy Khariton, M. Husain, S. Inzucchi, D. McGuire, B. Pitt, B. Scirica, B. Austin, M. Drazner, Michael Fong, M. Givertz, R. Gordon, R. Jermyn, S. Katz, S. Lamba, D. Lanfear, S. Larue, J. Lindenfeld, M. Malone, K. Margulies, R. Mentz, R. Mutharasan, M. Pursley, G. Umpierrez, M. Kosiborod, A. Malik, Nannette Wenger, Modele Ogunniyi, P. Vellanki, B. Murphy, J. Newman, J. Hartupee, Charu Gupta, Marcela Goldsmith, Paramdeep Baweja, M. Montero, S. Gottlieb, M. Costanzo, Thanh Hoang, A. Warnock, L. Allen, Wilson Tang, Horng Chen, J. Cox (2019)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.Circulation
S. Jabbour, J. Seufert, A. Scheen, C. Bailey, C. Karup, A. Langkilde (2017)
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trialsDiabetes, Obesity & Metabolism, 20
M. Cheitlin (2007)
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart FailureYearbook of Cardiology, 2007
H. Hillege, D. Nitsch, M. Pfeffer, K. Swedberg, J. McMurray, S. Yusuf, C. Granger, E. Michelson, J. Östergren, J. Cornel, D. Zeeuw, S. Pocock, D. Veldhuisen (2006)
Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart FailureCirculation, 113
M Writing Committee (2013)
e240Circulation, 128
M. Weber, T. Mansfield, V. Cain, N. Iqbal, S. Parikh, A. Ptaszynska (2016)
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.The lancet. Diabetes & endocrinology, 4 3
A. Bui, T. Horwich, G. Fonarow (2011)
Epidemiology and risk profile of heart failureNature Reviews Cardiology, 8
C. Wanner, J. Lachin, S. Inzucchi, D. Fitchett, M. Mattheus, J. George, H. Woerle, U. Broedl, M. Eynatten, B. Zinman (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney DiseaseCirculation, 137
M. Packer, S. Anker, J. Butler, G. Filippatos, F. Zannad (2017)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of ActionJAMA Cardiology, 2
M. Kosiborod, I. Gause-Nilsson, John Xu, C. Sonesson, E. Johnsson (2017)
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.Journal of diabetes and its complications, 31 7
D. Fitchett, J. Butler, P. Borne, B. Zinman, J. Lachin, C. Wanner, H. Woerle, S. Hantel, J. George, O. Johansen, S. Inzucchi (2018)
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trialEuropean Heart Journal, 39
I. Neeland, Darren Mcguire, R. Chilton, S. Crowe, S. Lund, H. Woerle, U. Broedl, O. Johansen (2016)
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitusDiabetes & Vascular Disease Research, 13
B. Baujat, C. Mahé, J. Pignon, C. Hill (2002)
A graphical method for exploring heterogeneity in meta‐analyses: application to a meta‐analysis of 65 trialsStatistics in Medicine, 21
J. Higgins, S. Thompson (2002)
Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 21
K. Docherty, P. Jhund, I. Anand, O. Bengtsson, M. Böhm, R. Boer, D. DeMets, Akshay Desai, J. Drożdż, J. Howlett, S. Inzucchi, P. Johanson, T. Katova, L. Køber, M. Kosiborod, A. Langkilde, D. Lindholm, F. Martinez, B. Merkely, J. Nicolau, E. O’Meara, P. Ponikowski, M. Sabatine, M. Sjöstrand, S. Solomon, S. Tereshchenko, S. Verma, J. McMurray (2020)
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection FractionCirculation, 142
D. Moher, A. Liberati, J. Tetzlaff, D. Altman (2009)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statementThe BMJ, 339
M. Packer, P. Carson, U. Elkayam, M. Konstam, G. Moe, C. O'connor, J. Rouleau, D. Schocken, S. Anderson, D. DeMets (2013)
Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2).JACC. Heart failure, 1 4
Eri Kato, Michael Silverman, Ofri Mosenzon, Thomas Zelniker, A. Cahn, Remo Furtado, J. Kuder, S. Murphy, Deepak Bhatt, L. Leiter, D. McGuire, John Wilding, Marc Bonaca, C. Ruff, Akshay Desai, S. Goto, P. Johansson, I. Gause-Nilsson, P. Johanson, A. Langkilde, I. Raz, M. Sabatine, S. Wiviott (2019)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.Circulation, 139 22
E. Araki, Y. Onishi, Michiko Asano, Hyosung Kim, T. Yajima (2017)
Efficacy and safety of dapagliflozin over 1 year as add‐on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trialDiabetes, 19
S. Wiviott, Itamar Raz, M. Sabatine (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.The New England journal of medicine, 380 19
A. Baartscheer, C. Schumacher, R. Wüst, J. Fiolet, G. Stienen, R. Coronel, C. Zuurbier (2016)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbitsDiabetologia, 60
M. Mehra, M. Vaduganathan, Minghuan Fu, J. Ferreira, S. Anker, J. Cleland, C. Lam, D. Veldhuisen, W. Byra, T. Spiro, H. Deng, F. Zannad, B. Greenberg (2019)
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trialEuropean Heart Journal, 40
E. Benjamin, P. Muntner, Á. Alonso, M. Bittencourt, C. Callaway, A. Carson, A. Chamberlain, Alexander Chang, Susan Cheng, Sandeep Das, F. Delling, L. Djoussé, M. Elkind, J. Ferguson, M. Fornage, L. Jordan, S. Khan, B. Kissela, K. Knutson, T. Kwan, D. Lackland, T. Lewis, J. Lichtman, C. Longenecker, M. Loop, P. Lutsey, S. Martin, K. Matsushita, Andrew Moran, M. Mussolino, M. O’Flaherty, A. Pandey, A. Perak, W. Rosamond, Gregory Roth, Uchechukwu Sampson, G. Satou, Emily Schroeder, Svati Shah, Nicole Spartano, A. Stokes, D. Tirschwell, C. Tsao, M. Turakhia, L. VanWagner, J. Wilkins, Sally Wong, S. Virani (2019)
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart AssociationCirculation, 139
S. Anker, J. Butler, G. Filippatos, W. Jamal, A. Salsali, J. Schnee, K. Kimura, C. Zeller, J. George, M. Brueckmann, F. Zannad, M. Packer (2019)
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved TrialEuropean Journal of Heart Failure, 21
D. Fitchett, B. Zinman, C. Wanner, J. Lachin, S. Hantel, A. Salsali, O. Johansen, H. Woerle, U. Broedl, S. Inzucchi (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trialEuropean Heart Journal, 37
M. Usman, T. Siddiqi, M. Memon, M. Khan, W. Rawasia, Muhammad Ayub, Jayakumar Sreenivasan, Y. Golzar (2018)
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysisEuropean Journal of Preventive Cardiology, 25
J. Menne, E. Dumann, H. Haller, B. Schmidt (2019)
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysisPLoS Medicine, 16
M. Packer, J. Butler, G. Filippatos, W. Jamal, A. Salsali, J. Schnee, K. Kimura, C. Zeller, J. George, M. Brueckmann, S. Anker, F. Zannad (2019)
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trialEuropean Journal of Heart Failure, 21
R. DeFronzo, L. Norton, M. Abdul-Ghani (2017)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibitionNature Reviews Nephrology, 13
BackgroundSeveral clinical trials of dapagliflozin in patients with type 2 diabetes mellitus (T2DM) at elevated cardiovascular risk have observed reduced hospitalization for heart failure (HHF). Several studies have also suggested cardiovascular benefits for patients with HF regardless of whether or not they have T2DM.ObjectiveThis meta-analysis was conducted to evaluate the therapeutic effects of dapagliflozin in patients with HF.MethodsThe PubMed, Embase, Cochrane Library, and Web of Science databases were systematically searched from database inception to 15 February 2020. Clinical studies of dapagliflozin use in patients with HF were included. Data on HHF, all-cause mortality, cardiovascular death, major adverse cardiovascular events (MACE), systolic blood pressure, body weight, glycated hemoglobin (HbA1c), and adverse events were collected for analysis.ResultsFour randomized controlled trials involving 6738 patients with HF were included in this meta-analysis. Patients receiving dapagliflozin showed a significantly lower incidence of HHF [risk ratio (RR) 0.72; P < 0.00001], all-cause mortality (RR 0.83; P = 0.004), cardiovascular death (RR 0.86; P = 0.03), and MACE (RR 0.88; P = 0.03). Moreover, patients receiving dapagliflozin also showed significant improvements in systolic blood pressure and body weight. However, no statistical difference was observed in HbA1c. In addition, hypoglycemia, volume depletion, and renal impairment was not more frequent with dapagliflozin than with placebo.ConclusionThis meta-analysis suggests that dapagliflozin could be a therapeutic strategy for patients with HF regardless of the presence or absence of T2DM.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Oct 1, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.